Athira Pharma, Inc. - Schedule 13G Filing

This filing concerns Athira Pharma, Inc. and reports beneficial ownership information as of November 18, 2025. The percentages are based on 9,604,313 shares of Common Stock outstanding. ACORN BIOVENTURES, L.P. holds 210,730 shares, representing 2.2% ownership. ACORN CAPITAL ADVISORS GP, LLC, as the general partner, may be deemed to beneficially own these shares. ACORN BIOVENTURES 2, L.P. holds 291,009 shares, representing 3.0% ownership. Acorn Capital Advisors GP 2, LLC, as the general partner, may be deemed to beneficially own these shares. Anders Hove, as Manager of both general partners, may be deemed to beneficially own a total of 501,739 shares, representing 5.2% ownership. The filing includes certifications that these securities were not acquired or held for the purpose of changing or influencing the control of the issuer.